The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.

[1]  Xiaoyu Liu,et al.  Bradykinin/bradykinin 1 receptor promotes brain microvascular endothelial cell permeability and proinflammatory cytokine release by downregulating Wnt3a , 2022, Journal of biochemical and molecular toxicology.

[2]  D. Rex,et al.  A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases , 2022, Molecular Biology Reports.

[3]  D. Proud,et al.  Respiratory Viral and Bacterial Exacerbations of COPD—The Role of the Airway Epithelium , 2022, Cells.

[4]  G. Donaldson,et al.  Update in Chronic Obstructive Pulmonary Disease in 2020. , 2021, American Journal of Respiratory and Critical Care Medicine.

[5]  J. Hohlfeld,et al.  Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge. , 2020, Pulmonary pharmacology & therapeutics.

[6]  B. Balbi,et al.  Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease , 2020, Annals of medicine.

[7]  D. McAuley,et al.  Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation , 2020, European Respiratory Journal.

[8]  Wenbo Tang,et al.  Bradykinin 1 Receptor Antagonist BI1026706 Does Not Reduce Central Retinal Thickness in Center-Involved Diabetic Macular Edema , 2020, Translational vision science & technology.

[9]  F. Wacker,et al.  Noninvasive Monitoring of the Response of Human Lungs to Low‐Dose Lipopolysaccharide Inhalation Challenge Using MRI: A Feasibility Study , 2019, Journal of magnetic resonance imaging : JMRI.

[10]  A. Kirsten,et al.  Safety and Tolerability of Four Weeks' Treatment with a Bradykinin 1 Receptor Antagonist (BI 1026706) in Patients with COPD (GOLD I-III) , 2019, Therapy.

[11]  Steven,et al.  The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial , 2018, International journal of chronic obstructive pulmonary disease.

[12]  M. Bader,et al.  Kinin B1 receptors as a therapeutic target for inflammation , 2018, Expert opinion on therapeutic targets.

[13]  M. Boskabady,et al.  Experimental animal models for COPD: a methodological review , 2017, Tobacco induced diseases.

[14]  Dongwon Lee,et al.  Kinin B 1 Receptor Inhibition with BI 113823 Reduces Inflammatory Response , Mitigates Organ Injury , and Improves Survival in Severe Sepsis , 2015 .

[15]  Malarvizhi Gurusamy,et al.  Kinin B1 receptor antagonist BI113823 reduces allergen-induced airway inflammation and mucus secretion in mice. , 2016, Pharmacological research.

[16]  Malarvizhi Gurusamy,et al.  Kinin B1 Receptor Antagonist BI113823 Reduces Acute Lung Injury* , 2015, Critical care medicine.

[17]  Dave Singh,et al.  Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects , 2015, European Journal of Clinical Pharmacology.

[18]  Dave Singh,et al.  Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease. , 2015, British journal of clinical pharmacology.

[19]  M. Hernandez,et al.  IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. , 2015, The Journal of allergy and clinical immunology.

[20]  N. Alexis,et al.  Effect of inhaled endotoxin on mucociliary clearance and airway inflammation in mild smokers and nonsmokers. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[21]  O. Michel,et al.  Anti-TNF inhibits the Airways neutrophilic inflammation induced by inhaled endotoxin in human , 2014, BMC Pharmacology and Toxicology.

[22]  Yi Wu,et al.  A role for bradykinin in the development of anti-collagen antibody-induced arthritis. , 2014, Rheumatology.

[23]  Frank K Wacker,et al.  Quantification of pulmonary inflammation after segmental allergen challenge using turbo-inversion recovery-magnitude magnetic resonance imaging. , 2014, American journal of respiratory and critical care medicine.

[24]  P. Barnes,et al.  Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist , 2013, Respiratory Research.

[25]  D. Postma,et al.  Expression of vascular remodelling markers in relation to bradykinin receptors in asthma and COPD , 2013, Thorax.

[26]  N. Krug,et al.  Low-dose endotoxin inhalation in healthy volunteers - a challenge model for early clinical drug development , 2013, BMC Pulmonary Medicine.

[27]  Dave Singh,et al.  Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. , 2012, British journal of clinical pharmacology.

[28]  M. Elmlinger,et al.  Repeatability of and Relationship between Potential COPD Biomarkers in Bronchoalveolar Lavage, Bronchial Biopsies, Serum, and Induced Sputum , 2012, PloS one.

[29]  M. Hernandez,et al.  Atopic asthmatic patients have reduced airway inflammatory cell recruitment after inhaled endotoxin challenge compared with healthy volunteers. , 2012, The Journal of allergy and clinical immunology.

[30]  L. Larsson,et al.  Microbiological components in mainstream and sidestream cigarette smoke , 2012, Tobacco induced diseases.

[31]  E. Vaucher,et al.  Ocular Application of the Kinin B1 Receptor Antagonist LF22-0542 Inhibits Retinal Inflammation and Oxidative Stress in Streptozotocin-Diabetic Rats , 2012, PloS one.

[32]  I. Du Rand,et al.  Summary of the British Thoracic Society Guidelines for advanced diagnostic and therapeutic flexible bronchoscopy in adults , 2011, Thorax.

[33]  A. Morin,et al.  Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells , 2011, Peptides.

[34]  F. Marceau,et al.  Effect of interferon-γ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells. , 2010, European journal of pharmacology.

[35]  A. Morin,et al.  Mechanism of cigarette smoke-induced kinin B1 receptor expression in rat airways , 2010, Peptides.

[36]  D. Rand,et al.  Dual positive and negative regulation of GPCR signaling by GTP hydrolysis. , 2009, Cellular signalling.

[37]  N. Krug,et al.  Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. , 2008, Pulmonary pharmacology & therapeutics.

[38]  N. Krug,et al.  Endotoxin augments myeloid dendritic cell influx into the airways in patients with allergic asthma. , 2008, American journal of respiratory and critical care medicine.

[39]  R. Kitz,et al.  Systemic and bronchial inflammation following LPS inhalation in asthmatic and healthy subjects , 2006, Journal of endotoxin research.

[40]  K. Bhoola,et al.  Activation of kinin B1 receptors induces chemotaxis of human neutrophils , 2006, Journal of leukocyte biology.

[41]  W. Abraham,et al.  Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. , 2006, European journal of pharmacology.

[42]  D. Patel,et al.  Acute LPS inhalation in healthy volunteers induces dendritic cell maturation in vivo. , 2005, The Journal of allergy and clinical immunology.

[43]  Joachim Heinrich,et al.  Metal-rich ambient particles (particulate matter 2.5) cause airway inflammation in healthy subjects. , 2004, American journal of respiratory and critical care medicine.

[44]  N. Krug,et al.  Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. , 2004, American journal of respiratory and critical care medicine.

[45]  R. Chang,et al.  Molecular and pharmacological diversity of the kinin B1 receptor. , 2002, International immunopharmacology.

[46]  S. Banks,et al.  Local inflammatory responses following bronchial endotoxin instillation in humans. , 2001, American journal of respiratory and critical care medicine.

[47]  L. M. Leeb-Lundberg,et al.  The Human B1 Bradykinin Receptor Exhibits High Ligand-independent, Constitutive Activity , 2001, The Journal of Biological Chemistry.

[48]  J. Hasday,et al.  Bacterial endotoxin is an active component of cigarette smoke. , 1999, Chest.

[49]  R. Sergysels,et al.  Dose-response relationship to inhaled endotoxin in normal subjects. , 1997, American journal of respiratory and critical care medicine.

[50]  R. Sergysels,et al.  Inflammatory response to acute inhalation of endotoxin in asthmatic patients. , 1992, The American review of respiratory disease.

[51]  J. Hohlfeld,et al.  The inhibition of α1-adrenoceptor-mediated contractions of rabbit pulmonary artery by Ca2+-withdrawal, pertussis toxin and N-ethylmaleimide is dependent on agonist intrinsic efficacy , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[52]  P. Barnes,et al.  Bradykinin-induced bronchoconstriction in humans. Mode of action. , 1987, The American review of respiratory disease.